Skip to main content
Log in

High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML)

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Costimulatory molecules such as lymphocyte function-associated antigen (LFA)-1 (CD11a), LFA-3 (CD58), intercellular adhesion molecule (ICAM)-1 (CD54), neuronal cell adhesion molecule (NCAM) (CD56), B7-1 (CD80), or B7-2 (CD86) are important regulatory elements in healthy immunological cascades, but their role in acute myeloid leukemia (AML) has only been rarely investigated. We studied their expression on mononuclear bone marrow (BM) cells from 105 patients with AML at initial diagnosis and evaluated their prognostic significance. Fluorescence-activated cell sorter (FACS) analyses were performed using antibodies directly conjugated with fluorescein. A BM sample was considered positive if more than 20% of the cells in the blast containing gate expressed the respective marker. The surface expression of CD11a (27 of 29 cases positive with an average of 71% positive blasts; 27+/29, 71%), CD54 (23+/33, 37%), CD56 (24+/93, 20%), CD58 (29+/29, 95%), CD80 (13+/28, 30%), and CD86 (19+/29, 39%) was measured. The expression of these markers in different French-American-British (FAB) classification types (M0–M5) was heterogeneous, except for CD56, which showed a higher proportion of positive cells in monocytic subtypes of AML. In addition, cases with a “poor risk” karyotype as well as patients succumbing to “early death” after double induction therapy according to the AML Cooperative Group (CG) protocol were characterized by a high expression of CD56. Relapse-free survival analyses demonstrated that patients with more than 8% CD56+ cells in the BM relapsed significantly sooner. CD54 was preferentially expressed in AML M4eo and in addition in “favorable” cytogenetic risk groups and in cases that had responded to AML-CG therapy. Only very high proportions (>60%) of CD54+ cells were associated with a lower probability for relapse-free survival. CD80 and CD86 expressions were similar in all FAB types. Patients who had responded to AML-CG therapy showed higher CD80 proportions and lower CD86 proportions compared to the “nonresponder” group. Whereas cases with more than 15% CD80+ cells had a significantly lower probability for relapse-free survival, only cases with more than 65% CD86+ were characterized by a significantly lower probability for relapse-free survival. Expression profiles of CD11a and CD58 were not associated with specific FAB types or prognostically relevant groups. We can conclude: (1) Expression of costimulatory molecules in AML is very variable. This reflects the great diversity of immunophenotypes in AML. (2) CD56 is mainly expressed in monocytic subtypes of AML. CD56+ subtypes of AML seem to be a separate entity with a worse prognosis independent of the karyotype. (3) High expression of some costimulatory molecules correlates with a worse prognosis concerning relapse-free survival times.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Allison JP, Krummel MF (1995) The yin and yang of T cell costimulation. Science 270:932–933

    CAS  PubMed  Google Scholar 

  2. Archimbaud E, Thomas X, Campos L, Magaud JP, Dore JF, Fiere D (1992) Expression of surface adhesion molecules CD54 (ICAM-1) and CD58 (LFA-3) in adult acute leukemia: relationship with initial characteristics and prognosis. Leukemia 6:265–271

    CAS  PubMed  Google Scholar 

  3. Baer MR, Stewart CC, Lawrence D, Arthur CD, Byrd CJ, Davey FR et al (1997) Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 4:1643–1648

    Google Scholar 

  4. Bendall LJ, Kortlepel K, Gottlieb DJ (1995) GM-CSF enhances IL-2-activated natural killer cell lysis of clonogenic AML cells by upregulating target cell expression of ICAM-1. Leukemia 9:689–699

    Google Scholar 

  5. Bene MC, Bernier M, Castoldi G, Knapp W, Ludwig WD, Matutes E et al (1995) Proposals for the immunological classification of acute leukaemias. Leukemia 9:1783–1788

    CAS  PubMed  Google Scholar 

  6. Bennett JM, Catovsky D, Daniel MT et al (1985) Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103:626–629

    PubMed  Google Scholar 

  7. Brouwer RE, van der Hoorn M, Kluin-Nelemans HC, van Zelderen-Bhola S, Willemze R, Falkenburg JHF (2000) The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses. Hum Immunol 61:565–574

    Article  CAS  PubMed  Google Scholar 

  8. Brouwer RE, Zwinderman KH, Kluin-Nelemans HC, van Luxemburg-Heijs SAP, Willemze R, Falkenburg JHF (2000) Expression and induction of costimulatory and adhesion molecules on acute myeloid leukemic cells: implications for adoptive immunotherapy. Exp Hematol 28:161–168

    Article  CAS  PubMed  Google Scholar 

  9. Bruserud O (1999) Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future therapeutic strategies. Leukemia 13:1175–1187

    Article  CAS  PubMed  Google Scholar 

  10. Bruserud O, Wendelboe O (2001) Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy? Expert Opin Biol Ther 1:1005–1016

    CAS  PubMed  Google Scholar 

  11. Byrd JC, Edenfield WJ, Shields DS, Dawson NA (1995) Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. J Clin Oncol 13:1800–1816

    CAS  PubMed  Google Scholar 

  12. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao K, Watson MS, Koduru PRK, Moore JO, Stone RM, Mayer JR, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325–4336

    Article  CAS  PubMed  Google Scholar 

  13. Chen L, McGowan P, Ashe S, Johnston JV, Hellstrom I, Hellstrom KE (1994) B7-1/ CD80 transduced tumor cells elicit better systemic immunity than wild type tumor cells admixed with Corynebacterium parvum. Cancer Res 54:5420–5423

    CAS  PubMed  Google Scholar 

  14. De Waele M, Renmans W, Jochmans K, Schots R, Lacor P, Trullemanns F et al (1999) Different expression of adhesion molecules on CD34+ cells in AML and B-lineage ALL and their normal bone marrow counterparts. Eur J Haematol 63:163–201

    PubMed  Google Scholar 

  15. Fardoun-Joalland D, Teixeira-Lebrun G, Jonan-Beades F, Lenormand B, Dzondo-Gadet M, Vannier JP (1994) Sensitivity of myeloid progenitors to NK-cell depletion. Am J Hematol 47:290–294

    CAS  PubMed  Google Scholar 

  16. Gambacorti-Passerini C, Grignani F, Arienti F, Pandolfi PP, Pelicci PG, Parmiani G (1993) Human CD4 T lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RARa present in acute promyleocytic leukemic cells. Blood 81:1369–1375

    CAS  PubMed  Google Scholar 

  17. Harrison BD, Adams JA, Briggs M, Brereton ML, Yin JA (2001) Stimulation of autologous proliferative and cytotoxic T-cell responses by leukemic dendritic cells derived from blast cells in acute myeloid leukemia. Blood 97:2764–2771

    Article  CAS  PubMed  Google Scholar 

  18. Herberman RB, Reynolds CW, Ortaldo JR (1986) Mechanism of cytotoxicity by natural killer (NK) cells. Annu Rev Immunol 4:651–680

    Article  CAS  PubMed  Google Scholar 

  19. Hirano N, Takahashi T, Ohtake S, Hirashima K, Emi N, Saito K et al (1996) Expression of costimulatory molecules in human leukemias. Leukemia 10:1168–1176

    CAS  PubMed  Google Scholar 

  20. Iizuka Y, Aiso M, Oshimi K, Kanemaru M, Kawamura M, Takeuchi J et al (1993) Myeloblastoma formation in acute myeloid leukemia. Leuk Res 16:665–671

    Article  Google Scholar 

  21. Jones YE (1997) MHC class I and class II structures. Curr Opin Immunol 9:75–79

    Article  CAS  PubMed  Google Scholar 

  22. Kawada H, Fukuda R, Yoshida M, Takei M, Kobayashi N, Masumoto A et al (1996) Clinical significance of LFA-1 expression in adult acute myeloid leukemia. Leuk Res 20:327–332

    Article  CAS  PubMed  Google Scholar 

  23. Khalidi HS, Medeiros LJ, Chang KL, Bryes RK, Slovak ML, Arber DA (1998) The immunophenotype of adult acute myeloid leukemia: higher frequency of lymphoid antigen expression and comparison of immunophenotype, French–American–British classification and karyotypic abnormalities. Am J Clin Pathol 109:211–220

    CAS  PubMed  Google Scholar 

  24. Kuwabara H, Nagai M, Yamaoka G, Ohnishi H, Kawakami K (1999) Specific skin manifestations in CD56 positive acute myeloid leukemia. J Cutan Pathol 26:1–5

    Google Scholar 

  25. Lickliter JD, Kratzke RA, Nguyen P, Niehans GA, Miller JS (1998) Fas ligand is highly expressed by both normal hematopoietic progenitor cells and acute leukemic blasts (abstract). Blood 92 [Suppl 1]:227a

    Google Scholar 

  26. Maeda A, Yamamoto K, Yamashita K, Asagoe K, Nohgawa M, Kita K et al (1998) The expression of costimulatory molecules and their relationship to the prognosis of human acute myeloid leukemia: poor prognosis of B7-2-positive leukemia. Br J Haematol 102:1257–1262

    Article  CAS  PubMed  Google Scholar 

  27. Makoba MW, Sanders ME, Shaw S (1990) The CD2-LFA-3 and LFA-1-ICAM pathways: relevance to T-cell recognition. Immunol Today 10:417–422

    Article  Google Scholar 

  28. Mazumdar M, Glassman JR (2000) Tutorial in biostatistics. Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatment. Stat Med 19:113–132

    Article  CAS  PubMed  Google Scholar 

  29. Mitelman K (1995) ISCN. An international system for human cytogenetic nomenclature. Karger, Basel

    Google Scholar 

  30. Moingeon P, Chang HC, Wallner BP, Stebbius C, Frey AZ, Reinherz EL (1989) CD2-mediated adhesion facilitates T lymphocyte antigen recognition function. Nature 339:312–314

    Article  CAS  PubMed  Google Scholar 

  31. Mrozek K, Heinonen K, de la Chapelle A, Bloomfield CD (1997) Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 24:17–31

    CAS  PubMed  Google Scholar 

  32. Munker R, Andreff M (1996) Induction of death (CD95/FAS), activation and adhesion (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-alpha and IFN-gamma. Cytokines Mol Ther 2:147–160

    CAS  PubMed  Google Scholar 

  33. Oblakowski P, Bello-Fernandez C, Rettie JE, Heslop HE, Galatowicz G, Veys P et al (1991) Possible mechanism of selective killing of myeloid leukemic blast cells by lymphokine-activated killer cells. Blood 77:1996–2001

    CAS  PubMed  Google Scholar 

  34. Palucka AK, Prowit A, Reizenstein P (1992) A supportive role of neural cell adhesion molecule (NCAM) in adhesion between leukaemic blasts and cytotoxic lymphocytes. Scand J Immunol 35:399–406

    CAS  PubMed  Google Scholar 

  35. Pancook JD, Reisfeld RA, Varki N, Vitiello A, Foy RI, Montgomery AM (1997) Expression and regulation of neural cell adhesion molecule L1 on human cells of myelomonocytic and lymphoid origin. J Immunol 158:4413–4421

    CAS  PubMed  Google Scholar 

  36. Paul WE (Ed) (1999) Fundamental immunology, 3rd edn. Raven Press, New York, p 1160

    Google Scholar 

  37. Raspadori D, Lauria F, Ventura MA, Rondelli D, Tura S (1993) Expression of adhesion molecules on acute leukemic blast cells and sensitivity to normal LAK activity. Ann Hematol 67:213–216

    CAS  PubMed  Google Scholar 

  38. Reif S, Wiesner D, Duell T, Mittermueller J, Schmetzer H (2001) Not the presence but the amount of clonal DNA detectable in remission of acute myeloid leukemia (AML) is predictive for relapse. Eur J Haematol 67:207–222

    Article  CAS  PubMed  Google Scholar 

  39. Reuss-Borst MA, Klein G, Waller HD, Müller CA (1995) Differential expression of adhesion molecules in acute leukemia. Leukemia 9:869–872

    CAS  PubMed  Google Scholar 

  40. Rothe G, Schmitz G, Working Group on Flow Cytometry and Image Analysis (1996) Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Leukemia 10:877–895

    CAS  PubMed  Google Scholar 

  41. Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, Haferlach T (2003) AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 102:2395–2402

    Article  CAS  PubMed  Google Scholar 

  42. Scott AA, Head DR, Kopecky KJ, Appelbaum FR, Theil KS, Grever MR et al (1994) HLA-DR−, CD33+, CD56+, CD16− myeloid/natural killer cell acute leukemia: a previous unrecognized form of acute leukemia potentially misdiagnosed as French–American–British acute myeloid leukemia-M3. Blood 84:2824–2825

    PubMed  Google Scholar 

  43. Seymour JF, Pierce SA, Kantarjian HM, Keating MJ, Estey EH (1994) Investigations of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). Leukemia 8:823–826

    CAS  PubMed  Google Scholar 

  44. Thomas X, Vila L, Campos L, Sabido O, Archimbaud E (1995) Expression of N-CAM (CD56) on acute leukemia cells: relationship with disease characteristics and outcome. Leuk Lymphoma 19:295–300

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Mr. Oliver Schiekl for skillful technical assistance and Professor T. Haferlach and PD Dr. C. Schoch, both Medical Department III, Klinikum Groβhadern, for placing at our disposal patients’ data and diagnostic reports.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to H. Schmetzer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Graf, M., Reif, S., Hecht, K. et al. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML). Ann Hematol 84, 287–297 (2005). https://doi.org/10.1007/s00277-004-0978-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-004-0978-0

Keywords

Navigation